Published in Bioorg Med Chem Lett on November 18, 2002
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med (2009) 1.76
Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem (2004) 1.67
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 1.62
Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol (2004) 1.61
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett (2008) 1.60
Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov (2011) 1.45
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell (2007) 1.35
The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes (2009) 1.32
Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem (2004) 1.29
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Statistical and graphical methods for quality control determination of high-throughput screening data. J Biomol Screen (2003) 1.27
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol (2006) 1.24
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther (2008) 1.23
MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom (2007) 1.20
Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin. J Pharmacol Exp Ther (2002) 1.16
An Australian casemix classification for palliative care: lessons and policy implications of a national study. Palliat Med (2004) 1.08
Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell (2010) 1.07
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg Med Chem Lett (2006) 1.06
Discovery, biosynthesis, and structure elucidation of metabolites of a doping agent and a direct analogue, tetrahydrogestrinone and gestrinone, using human hepatocytes. Anal Chem (2005) 1.06
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett (2007) 1.05
Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol (2003) 1.05
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem (2005) 1.04
Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging (2012) 1.03
Identification of transforming growth factor beta1-driven genetic programs of acute lung fibrosis. Am J Respir Cell Mol Biol (2008) 1.03
Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther (2006) 1.02
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem (2004) 1.00
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol (2009) 1.00
The last drag: an evaluation of an LGBT-specific smoking intervention. J Homosex (2012) 0.99
Bioinformatic analysis reveals cRel as a regulator of a subset of interferon-stimulated genes. J Interferon Cytokine Res (2008) 0.99
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem (2011) 0.97
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett (2003) 0.97
Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry (2002) 0.97
Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant (2005) 0.97
Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis (2008) 0.96
Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor. Anal Chem (2008) 0.95
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem (2007) 0.95
The development of Version 2 of the AN-SNAP casemix classification system. Aust Health Rev (2007) 0.95
Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol (2007) 0.95
Transport and deposition of sediment-associated Escherichia coli in natural streams. Water Res (2005) 0.94
p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorg Med Chem Lett (2006) 0.94
Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg Med Chem Lett (2006) 0.94
Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett (2009) 0.93
Substituted coumarins as potent 5-lipoxygenase inhibitors. Bioorg Med Chem Lett (2006) 0.93
An Australian casemix classification for palliative care: technical development and results. Palliat Med (2004) 0.93
Down-regulation of microsomal prostaglandin E2 synthase-1 in adipose tissue by high-fat feeding. Obesity (Silver Spring) (2007) 0.93
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species. Eur J Pharmacol (2007) 0.92
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem (2007) 0.92
Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem Pharmacol (2002) 0.92
Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine (2010) 0.92
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem (2005) 0.91
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14. Bioorg Med Chem Lett (2011) 0.91
An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal Biochem (2004) 0.91
Gold nanorods carrying paclitaxel for photothermal-chemotherapy of cancer. Bioconjug Chem (2013) 0.91
Clinical specialists and advanced practitioners in physical therapy: a survey of physical therapists and employers of physical therapists in ontario, Canada. Physiother Can (2008) 0.91
A potential link between autoimmunity and neurodegeneration in immune-mediated neurological disease. J Neuroimmunol (2011) 0.89
Murine central and peripheral nervous system transcriptomes: comparative gene expression. Brain Res (2006) 0.88
Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol (2007) 0.88
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res (2004) 0.87
Purification and characterization of recombinant microsomal prostaglandin E synthase-1. Protein Expr Purif (2002) 0.87
Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol (2004) 0.87
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum (2013) 0.86
Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS. J Lipid Res (2006) 0.86
Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta (2006) 0.86
In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol Pharmacol (2008) 0.86
Chemical genomics of cancer chemopreventive dithiolethiones. Carcinogenesis (2009) 0.86
Proposed guidelines for clenbuterol food poisoning. Am J Med (2004) 0.85
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists. Bioorg Med Chem Lett (2011) 0.85
Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett (2006) 0.85
Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators. Br J Pharmacol (2002) 0.85
Health services research and development in practice: an Australian experience. J Health Serv Res Policy (2003) 0.85
Multiple comparisons model-based clustering and ternary pattern tree numerical display of gene response to treatment: procedure and application to the preclinical evaluation of chemopreventive agents. Mol Cancer Ther (2002) 0.85